I read with great interest the article by Sun et al. [1]. Pentoxifylline may exert a number of renoprotective effects, besides its role in attenuating diabetic nephropathy. Pentoxifylline attenuates kidney damage secondary to hepatic ischemia/reperfusion injury. It mediates this action by decreasing malondialdehyde levels [2]. Simultaneously, it restores intracellular glutathione. As a result, oxidative injury to the kidneys is mitigated. Obviously, conditions such as hepato-renal syndrome can be avoided with pentoxifylline pretreatment. The coming years may very well see increased use of pentoxifylline as a prophylactic agent to prevent hepatorenal syndrome in patients with concurrent cirrhosis and ascites.
Pentoxifylline is also beneficial in chronic renal disease. It benefits the kidneys by stabilizing renal function and the glomerular filtration rate. Concurrent decreases in inflammatory markers such as tissue necrosis factor-α and high-sensitivity C-reactive protein reflect the attenuation of inflammatory damage in the kidneys. The interleukin-6 level also decreases at the same time [3]. In addition, pentoxifylline helps reduce proteinuria in chronic kidney disease (CKD) patients. Renke et al. [3] recently reported a 26% decline in proteinuria following pentoxifylline therapy in comparison with placebo therapy. Pentoxifylline also decreases proteinuria in CKD patients following renal transplantation. Moreover, pentoxifylline modulates hepcidin function and augments iron release, thereby improving hemoglobin levels in CKD patients.
By virtue of its antioxidant properties, pentoxifylline also mitigates and reduces renal damage secondary to exposure to cigarette smoke. Similarly, pentoxifylline is of benefit in cardiac surgery because it prevents and attenuates acute renal injury [4]. When used in conjunction with albumin, pentoxifylline protects the kidneys from injury following endotoxemic shock, by decreasing inducible nitric oxide synthase expression in the kidneys [5]. Similarly, the postlaparoscopy administration of pentoxifylline attenuates renal ischemia associated with laparoscopy.
These examples clearly illustrate the renoprotective effects of pentoxifylline.
No potential conflict of interest relevant to this article is reported.
SunHKLeeYMHanKHKimHSAhnSHHanSYPhosphodiesterase inhibitor improves renal tubulointerstitial hypoxia of the diabetic rat kidneyKorean J Intern Med20122716317022707888SeifiBKadkhodaeeMDelavariFMikaeiliSShamsSOstadSNPretreatment with pentoxifylline and N-acetylcysteine in liver ischemia reperfusion-induced renal injuryRen Fail20123461061522364443RenkeMTylickiLRutkowskiPEffect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease: placebo controlled, randomized, cross-over studyActa Biochim Pol20105711912320309434BarkhordariKKarimiAShafieeAEffect of pentoxifylline on preventing acute kidney injury after cardiac surgery by measuring urinary neutrophil gelatinase-associated lipocalinJ Cardiothorac Surg20116821247431BansalSWangWFalkSSchrierRCombination therapy with albumin and pentoxifylline protects against acute kidney injury during endotoxemic shock in miceRen Fail20093184885419925295In replySunHui-KyoungHanSang-YoubDivision of Nephrology, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea.
Correspondence to Sang-Youb Han, M.D. Division of Nephrology, Department of Internal Medicine, Inje University Ilsan Paik Hospital, 170 Juhwa-ro, Ilsanseo-gu, Goyang 411-706, Korea. Tel: +82-31-910-7884, Fax: +82-31-910-7219, hansy@paik.ac.kr
We thank Dr. Kapoor for the precise comments on the effect of pentoxifylline (PTX) in diabetic nephropathy [1] and other diseases.
Currently, PTX is used to treat peripheral vascular and bronchoconstrictive diseases [2,3]. Recently, the effects of PTX have been determined under various conditions, including antiphospholipid syndrome, alcoholic hepatitis, and wound healing. Several clinical trials of PTX in nonalcoholic steatohepatiti), contrast-induced nephropathy, radiation injury, and other conditions have been conducted.
Unfortunately, the effects of PTX in patients with diabetic nephropathy are unclear. This might be due to the heterogeneous clinical nature of diabetic nephropathy. Of diabetics with chronic kidney disease, 24% to 51% do not have albuminuria [4,5]. The resistance of the intrarenal arteries was increased in type 2 diabetics with impaired renal function regardless of proteinuria [6]. These findings suggest that vasculopathy is a very important risk factor for the progression of diabetic nephropathy. Therefore, the effect of PTX in diabetic patients could differ according to the vascular changes.
No potential conflict of interest relevant to this article is reported.
SunHKLeeYMHanKHKimHSAhnSHHanSYPhosphodieste rase inhibitor improves renal tubulointerstitial hypoxia of the diabetic rat kidneyKorean J Intern Med20122716317022707888BoolellMAllenMJBallardSASildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunctionInt J Impot Res1996847528858389TeixeiraMMGristwoodRWCooperNHellewellPGPhosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?Trends Pharmacol Sci1997181641719184477KramerHJNguyenQDCurhanGHsuCYRenal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitusJAMA20032893273327712824208RetnakaranRCullCAThorneKIAdlerAIHolmanRRUKPDS Study GroupRisk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74Diabetes2006551832183916731850MacIsaacRJPanagiotopoulosSMcNeilKJIs nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease?Diabetes Care2006291560156616801579